J&J Wrongful Death Lawsuit Alleges Recalled Tylenol Link
This article was originally published in The Tan Sheet
The Tylenol product was from among the recalled lots, but remained available to “preserve the continuation of their billion dollar revenue stream,” the suit alleges. Serious adverse events did not prompt the recalls, which were announced comprehensively, the firm says.
You may also be interested in...
Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.
Johnson & Johnson pushes back to 2012 the target for returning its full slate of recalled OTC drugs to market as it adjusts to operating under a consent decree with FDA and the Department of Justice.
Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff